HEPATOTOXIC REACTIONS AND HEPATOPROTECTIVE THERAPY IN TUBERCULOSIS CONTROL
https://doi.org/10.21292/2075-1230-2015-0-8-48-53
Abstract
Несмотря на снижение заболеваемости и смертности от туберкулеза, эффективность лечения заболевания остается низкой и составляет в России среди впервые выявленных пациентов менее 69,6% по показателю прекращения бактериовыделения и 61,4% – по показателю закрытия деструкций. Среди рецидивов данные показатели еще ниже – 47,4 и 41,0% соответственно [6]. Это обусловлено, в первую очередь, ежегодным увеличением числа больных туберкулезом с множественной и широкой лекарственной устойчивостью возбудителя (МЛУ/ШЛУ МБТ), что создает серьезные медицинские и финансовые проблемы в здравоохранении.
About the Author
G. S. Balasanyants
St. Petersburg Research Institute of Phthisiopulmonology
Russian Federation
St. Petersburg
Russian Federation
St. Petersburg
References
1. WHO guidelines for the programmatic management of drug-resistant tuberculosis WHO/HTM/TB. 2006, 216 p. (In Russ.)
2. Emelyanyuk O.G. Diagnostika i lechenie porazheniy pecheni u bolnykh tuberkulezom legkikh v sledstvennom izolyatore (kliniko-instrumentalnoe issledovanie). Diss. kand. med. nauk. [Diagnostics and liver lesions in pulmonary tuberculosis patients in the remand prison (clinical and instrumental study). Cand. Diss.]. 2010, 24 p. 3. Ivanov А.K., Shevyreva E.V., Sakra А. et al. Hepatoprotective therapy of tuberculosis patients with concurrent viral hepatitis and HIV-infection. J. Infektologii, Prilozh., 2014, vol. 6, no. 2, pp. 43.
3. Markhaev А.G., Ubeeva I.P., Badleeva M.V Phytotherapy for management of hepatotoxic reactions to tuberculosis chemotherapy. Bulleten' VSNTS SO RAMN, 2010, no. 2 (72), pp. 67-70. (In Russ.)
4. International Statistical Classification of Diseases and Related Health Problems (ICD-10). (In Russ.)
5. Situatsiya po tuberkulezu i rabote protivotuberkuleznoy sluzhby Rossiyskoy Federatsii v 2013 g. Dannye Federal'nogo tsentra monitoringa protivodeystviya rasprostraneniyu tuberkuleza v Rossiyskoy Federatsii FGBU «TSNIIOIZ» Minzdrava Rossii. [Tuberculosis situation and activities of the Russian anti-tuberculosis services in 2013. Data of Federal Center of Monitoring of Tuberculosis Control and Prevention in the Russian Federation by CRIIPHO, Russian MoH]. 2014.
6. Sukhanov D.S. Antioxidative properties of remaxol, reamberin and adamethioninum in drug-induced liver lesions in patients having anti-tuberculosis treatment. Eksperim. i Klin. Parmakologiya, 2013, vol. 76, no. 4, pp. 45-48. (In Russ.)
7. Tkach S.M. Effektivnost' i bezopasnost' gepatoprotektorov s tochki zreniya dokazatel'noy meditsiny. [Efficiency and safety of hepatoprotectors from the position of the evidence-based medicine]. http://www.citofarma.ru/news/gepatoprotektory_ehffektivnost_i_bezopasnost/10-07-22
8. Khazanov B.A. Pharmacological regulation of energy exchange. Eksperim. i Klin. Parmakologiya, 2009, no. 4, vol. 72, pp. 61-64. (In Russ.)
9. Shevyreva E.V., Ivanov А.K., Sukhanov D.S. et al. Hepatoprotective therapy with remaxol for TB/HIV co-infected patients in the day center of TB dispensary. Antibiotiki i Khimioterapiya, 2012, vol. 57, no. 7-8, pp. 31-37. (In Russ.)
10. Shugaeva S.N. Aspects of pathogenic therapy of patients suffering from HIV-associated tuberculosis. Materialy nauchno-prakt. konf. s mezhdunar. uchastiem Bolezni organov dykhaniya: ot rebenka k vzroslomu. [Materials of Scientific Practical Conference with International Participation on Respiratory Diseases: from the Child to the Adult]. Chita, 2012.
11. Carrara E., Brunetti E., Di Matteo A. et al. Tubercular liver abscess: an uncommon presentation of disseminated tuberculosis. Infection, 2014, Nov 28. [Epub ahead of print]
12. Friedland G.V. Infectious disease comorbidities adversely affecting substance users with HIV: hepatitis C and tuberculosis. Acquir. Immune Defic. Syndr., 2010, vol. 55, suppl. 1, pp. 37-42.
13. Guglielmetti L., Le Dû D., Jachym M. et al. Compassionate Use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a french cohort. Clin. Infect. Dis., 2014, Oct 15. [Epub ahead of print]
14. Karunanithi S., Sharma P., Jain T.K. et al. Multiple hepatic lesions in a case of isolated hepatic tuberculosis simulating metastases on 18F-FDG PET/CT imaging./ http://www.ncbi.nlm.nih.gov/pubmed/25088112#
15. Liao J.R., Zhang D., Wu X.L. Pulmonary tuberculosis combined with hepatic tuberculosis: a case report and literature review./ http://www.ncbi.nlm.nih.gov/pubmed/24865423#
16. Pukenyte E., Lescure F.X., Rey D. et al. Incidence of and risk factors for severe liver toxicity in HIV-infected patients on anti-tuberculosis treatment. Int. J. Tuberc. Lung. Dis., 2007, vol. 11, no. 1, pp. 78-84.
17. Sahin M., Yılmaz G., Arhan M. et al. Hepatic granulomas in Turkey: A 6-year clinicopathological study of 35 cases. Turkey J.Gastroenterol., 2014, vol. 25, no. 5, pp. 524-528.
18. Santini D., Vincenzi B., Massaceisi C. et al. S-Adenosylmethionine supplementation for treatment of chemotherapy-induced liver injury. Anticancer Res., 2003, vol. 23, 6D, pp. 5173-5179.
19. Wu Y.C., Lo H.Y., Yang S.L. et al. Factors correlated with tuberculosis reported after death. Int. J. Tuberc. Lung. Dis., 2014, vol. 18, no. 12, pp. 1485-90.
20. Zinebi A., Rkiouak A., Akhouad Y. et al. Nodular hepatic tuberculosis: unusual complication during Wilson’s disease. Pan. Afr. Med. J., 2014, vol. 17, pp. 22.
Review
For citations:
Balasanyants G.S. HEPATOTOXIC REACTIONS AND HEPATOPROTECTIVE THERAPY IN TUBERCULOSIS CONTROL. Tuberculosis and Lung Diseases. 2015;(8):48-53. (In Russ.) https://doi.org/10.21292/2075-1230-2015-0-8-48-53
Views:
731
Email this article 